German biotechnology company Biontech and the American pharmaceutical industry Pfizer said on Monday that they will launch a very important global study to evaluate their top-ranked vaccine among potential vaccines for Covid-19 disease.
If the study is successful, the two companies will be able to submit the vaccine to obtain approval for inclusion in the regulations in October, putting their feet on the right track enabling them to save up to 100 million doses by the end of 2020 and 1.3 billion doses by the end of 2021.
Each patient is given two doses of the vaccine to help boost their immune system, so the first 100 million doses will be sufficient to vaccinate about 50 million people.
The study is expected to be conducted in about 120 places worldwide, and may include up to 30,000 participants. It will also include areas severely affected by the disease caused by the emerging corona virus.
“Launching Phase 2/3 is a major step forward in our progress towards providing a possible vaccine to help fight the Covid-19 pandemic,” said Catherine Jensen, Head of Vaccine Research and Development at Pfizer.
Pfizer (NYSE: PFE) already has an agreement to sell 100 million doses of its vaccine to the United States government, giving it the option to purchase 500 million additional doses. The company is in talks with other governments, including the European Union, on similar deals.